163 related articles for article (PubMed ID: 34686472)
1. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.
Brem EA; Li H; Beaven AW; Caimi PF; Cerchietti L; Alizadeh AA; Olin R; Henry NL; Dillon H; Little RF; Laubach C; LeBlanc M; Friedberg JW; Smith SM
J Geriatr Oncol; 2022 Mar; 13(2):258-264. PubMed ID: 34686472
[TBL] [Abstract][Full Text] [Related]
2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
Oberic L; Peyrade F; Puyade M; Bonnet C; Dartigues-Cuillères P; Fabiani B; Ruminy P; Maisonneuve H; Abraham J; Thieblemont C; Feugier P; Salles G; Bijou F; Pica GM; Damaj G; Haioun C; Casasnovas RO; Farhat H; Le Calloch R; Waultier-Rascalou A; Malak S; Paget J; Gat E; Tilly H; Jardin F
J Clin Oncol; 2021 Apr; 39(11):1203-1213. PubMed ID: 33444079
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi.
Merli F; Cavallo F; Salvi F; Tucci A; Musuraca G; Nassi L; Merli M; Tani M; Gini G; Ferrari A; Molinari AL; Liberati AM; Conconi A; Matteucci P; Bari A; Scalone R; Ferrero S; Zanni M; Mammi C; Luminari S
J Geriatr Oncol; 2020 Jan; 11(1):37-40. PubMed ID: 31296461
[TBL] [Abstract][Full Text] [Related]
6. A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.
Isaksen KT; Mastroianni MA; Rinde M; Rusten LS; Barzenje DA; Ramslien LF; Slaaen M; Jerm MB; Smeland EB; Rostoft S; Liestøl K; Brodtkorb M; Holte H
Blood Adv; 2021 Nov; 5(22):4771-4782. PubMed ID: 34543384
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
9. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Lin RJ; Owens CN; Drill E; Iannotta A; Oliveros M; Schick DL; Noy A; Gerecitano JF; Drullinsky PR; Caron PC; Kumar A; Matasar MJ; Moskowitz C; Korc-Grodzicki B; Zelenetz AD; Salles GA; Hamlin PA
Haematologica; 2022 May; 107(5):1144-1152. PubMed ID: 34289656
[TBL] [Abstract][Full Text] [Related]
10. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
11. Treatment Individualization in Diffuse Large B-Cell Lymphoma: Is Frailty Enough for Old Adults? An Original Article.
García-Baztán A; Oteiza-Olaso J; Gonzales-Montejo NJ; Ramón-Espinoza MF; Tamayo-Rodríguez I; Martínez-Velilla N; Viguria-Alegria MC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e348-e359. PubMed ID: 37487908
[TBL] [Abstract][Full Text] [Related]
12. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M; Huntington SF; Olszewski AJ
Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
[TBL] [Abstract][Full Text] [Related]
13. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.
Wu J; Song Y; Su L; Xu L; Chen T; Zhao Z; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Li X; Ouyang X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T; Feng J
BMC Cancer; 2016 Jul; 16():537. PubMed ID: 27460571
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
16. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
Khan Y; Brem EA
Curr Hematol Malig Rep; 2019 Aug; 14(4):228-238. PubMed ID: 31228094
[TBL] [Abstract][Full Text] [Related]
17. Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches.
Allen P
Curr Oncol Rep; 2020 Aug; 22(11):114. PubMed ID: 32827063
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment - A systematic review.
Tavares A; Moreira I
Crit Rev Oncol Hematol; 2021 Apr; 160():103294. PubMed ID: 33675907
[TBL] [Abstract][Full Text] [Related]
20. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
